GYRE THERAPEUTICS, INC.
About GYRE THERAPEUTICS, INC.
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $116.6M
- Net income
- $9.9M
- Total assets
- $166.1M
- Market cap
- $610.3M
- Gross margin
- 95.4%
- Operating margin
- 9.9%
- Net margin
- 8.5%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $116.6M
- Cost of revenue
- $5.4M
- Gross profit
- $111.2M
- Operating expenses
- $105.1M
- Operating income
- $11.5M
- Income tax
- $4.6M
- Net income
- $9.9M
- EPS (basic)
- $0.06
- EPS (diluted)
- $0.02
Balance sheet
- Total assets
- $166.1M
- Current assets
- $102.4M
- Total liabilities
- $23.9M
- Current liabilities
- $18.3M
- Shareholders’ equity
- $142.3M
Cash flow
- Operating cash flow
- $1.0M
- Investing cash flow
- -$474.0K
- Financing cash flow
- $24.4M
- Net cash flow
- $24.9M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $610.3M
- P/E ratio
- 302.5
- EPS (diluted)
- $0.02
- Shares outstanding
- 100.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 31, 2023
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $9.9M in FY2025.
- Revenue grew 3% from FY2023 to FY2025.
- Gross margin of 95.4%, net margin 8.5%.
- Trading 47% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 302.5.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review GYRE THERAPEUTICS, INC..
Write a review
News about GYRE THERAPEUTICS, INC.
News & sentiment via Polygon.io
